Direct technetium-99m labeling of anti-hepatoma monoclonal antibody fragment: a radioimmunoconjugate for hepatocellular carcinoma imaging

Table 1 Effect of molar ratio (Sn/GH: mAb) on quantity of-SH, free ^99mTcO₄- and colloid and labeling efficiency (%, n = 3)

Molar ratio(Sn/GH: mAb)	SH groups/mAb	99mTcO4-	colloid	labeling efficiency
Control	0 ± 0	62.1 ± 4.5	1.1 ± 1.2	2.0 ± 0.9
10:1	0.43 ± 0.04	3.0 ± 1.4	1.4 ± 1.1	44.6 ± 3.8
20:1	1.25 ± 0.10	2.9 ± 1.1	1.4 ± 0.7	72.8 ± 5.1
30:1	2.46 ± 0.08	2.0 ± 0.9	3.2 ± 1.4	78.6 ± 3.2
40:1	3.34 ± 0.09	1.8 ± 1.2	2.8 ± 1.3	84.2 ± 2.8
50:1	3.61 ± 0.12	2.1 ± 0.8	3.6 ± 1.5	84.4 ± 3.4

Table 2 Biodistribution of ^99mTc-HAb18 F(ab')₂ in nude mice bearing hepatoma (^-x±s,% ID/g)

Organ	Time after injection (h)
	4	10	24
Blood	2.21 ± 0.24	1.45 ± 0.15	0.56 ± 0.09
Kidney	72.38 ± 4.37	70.47 ± 15.23	56.45 ± 11.36
Liver	1.82 ± 0.48	1.59 ± 0.31	1.43 ± 0.27
Lung	1.62 ± 0.34	1.40 ± 0.17	0.75 ± 0.21
Stomach	1.37 ± 0.39	1.05 ± 0.28	0.50 ± 0.29
Spleen	2.35 ± 0.81	2.11 ± 0.75	1.82 ± 0.85
Large intestine	1.16 ± 0.34	1.42 ± 0.39	0.94 ± 0.32
Small intestine	0.97 ± 0.31	0.95 ± 0.18	0.62 ± 0.24
Heart	2.04 ± 0.55	1.83 ± 0.48	1.17 ± 0.42
Muscle	1.15 ± 0.20	0.77 ± 0.28	0.51 ± 0.25
Tumor	5.14 ± 2.26	5.84 ± 2.98	6.57 ± 3.01